.RESEARCH EMPHASIZE.16 October 2024.
In the NIAGARA litigation, the add-on of perioperative durvalumab to regular treatment for muscle-invasive sac cancer cells boosted event-free and in general survival, marking a brand new therapy possibility for this problem.